daclizumab   Click here for help

GtoPdb Ligand ID: 6880

Synonyms: L04AC01 | RO-24-7375 | Ro-247375 | Zenapax®
Approved drug Immunopharmacology Ligand
daclizumab is an approved drug (FDA FDA (1997), EMA (1999))
Compound class: Antibody
Comment: Daclizumab is a monoclonal antibody binding to the α subunit (CD25) of the high-affinity interleukin-2 receptor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

An advanced version of daclizumab, with identical primary sequence, but which is differentially gylcosylated, called daclizumab beta (BIIB019, DAC HYP) has been developed for subcutaneous administration. Daclizumab beta's alternate glycosylation pattern changes its binding to Fc receptors and reduces its propensity to induce complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).
Click here for help
No information available.
Summary of Clinical Use Click here for help
Originally approved to abrogate renal allograft rejection. Zenapax® was withdrawn from use, at the request of the marketing authorisation holder (Roche) for commercial reasons.
A Phase 2 clinical trial NCT01468311 investigating the use of radio-labelled daclizumab as part of the immunosuppressive conditioning regimen in preparation for stem cell transplant in Hodgkin's lymphoma patients was suspended before completion.

Daclizumab beta (BIIB019, produced in a high yield process) is being evaluated in Phase 2I clinical trial for relapsing-remitting multiple sclerosis (MS). Click here to view these Phase 2I trials at ClinicalTrials.gov. Pharmacokinetics of daclizumab beta are published in [3]. In May 2016, the US FDA approved the once-monthly daclizumab injection, Zinbryta® (which contains daclizumab beta) for the treatment of patients with relapsing forms of MS, but is only to be used for patients who have had an inadequate response to two or more MS drugs.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Abrogates the critical cellular immune response involved in allograft rejection by binding the CD25 subunit of the IL-2 receptor complex, preventing IL-2 binding and thereby inhibiting IL-2-mediated activation of lymphocytes.

In relapsing-remitting MS aberrant CD25 expression and abnormal activation of immune cells underlies the pathological demyelination of nerves. Daclizumab beta binding to CD25 is predicted to normalize immune cell activity, slowing the progress of the disease and reducing relapses [1].